retatrutide approval status fda ema 2025 Demand for Unapproved Weight-Loss Drug Surges on Social Media retatrutide approval status fda ema
Description
Some patients may continue medication long term, some may adjust the dose, and others may transition to a different maintenance plan

The table below shows where retatrutide stands with each of the five agencies and the projected approval windows, which are analyst estimates rather than confirmed dates

Where the differences occur though is probably their long-term risk

Broader metabolic coverage Metabolic syndrome involves multiple interconnected dysfunctions: insulin resistance, dyslipidemia, hypertension, visceral obesity, and chronic inflammation
The clinician can only work with the information you provide

NIH / NCBI Review: PubMed Clinical Data: Tirzepatide (NEJM): Disclaimer: GLP-1 medications, including Mounjaro (Tirzepatide) and Semaglutide, require a medical evaluation and are not suitable for everyone
